Real-World Patient Characteristics and Treatment Patterns Associated With Tucatinib Therapy in Patients With HER2+ Metastatic Breast Cancer
Jane Lowe Meisel, MD, presents data from a retrospective study investigating patient characteristics, treatment patterns, and clinical outcomes for tucatinib-based treatment in the real-world setting both overall and following fam-trastuzumab deruxtecan (T-DXd).
Jane Lowe Meisel Real World Patient Characteristics Patients With Metastatic Breast Lowe Meisel Her2 Metastatic Breast Cancer
Source: onclive.com